Home > Search Results

Results: 13

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients

Kidney transplantation is the treatment of choice for most patients with end‐stage renal disease (ESRD). Strategies to increase donor organ availability and to prolong the transplanted kidney's survival have become priorities in kidney transplantation. This review aimed to evaluate the short and long‐term benefits and harms of sirolimus and everolimus (TOR‐I) when used in primary immunosuppressive regimens for kidney transplant recipients. Thirty three trials investigating the use of TOR‐I in four different settings were evaluated in this review. No differences in the hard‐end points of patient and graft survival were demonstrated for or against TOR‐I in any comparison. Generally surrogate endpoints for graft survival favour TOR‐I (lower risk of acute rejection and higher GFR) and surrogate endpoints for patient outcomes are worsened by TOR‐I (bone marrow suppression, lipid disturbance). Long‐term hard‐endpoint data from methodologically robust randomised trials are still needed.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2009

Nivolumab (Opdivo) for advanced renal cell cancer: Overview

The drug nivolumab (trade name: Opdivo) has been approved in Germany since April 2016 for the treatment of advanced renal cell cancer. The drug is an option for adults who have already had treatment.

Informed Health Online [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: August 1, 2016

Lenvatinib (EU: Kisplyx, USA: Lenvima) for advanced renal cell cancer: Overview

The drug lenvatinib (trade name EU: Kisplyx, USA: Lenvima) has been approved in Germany since August 2016 for the treatment of advanced renal cell cancer.

Informed Health Online [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: January 26, 2017

Cabozantinib (Cabometyx) for advanced renal cell cancer: Overview

The drug cabozantinib (trade name: Cabometyx) has been approved in Germany since September 2016 for the treatment of advanced renal cell cancer.

Informed Health Online [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: February 23, 2017

Drugs that aim to relieve clinical symptoms of tuberous sclerosis complex

We reviewed the evidence about the effect of rapamycin or rapalogs for reducing the severity of clinical symptoms in people with tuberous sclerosis complex.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2016

Targeted drug therapy for advanced kidney cancer

Cancer of the kidney is an important health problem with over 15,000 deaths in North America annually. Kidney cancer in adults that has spread or is too advanced for surgery is incurable and is resistant to conventional chemotherapy drugs. Drugs that affect the body's immune system have been standard care in the past two decades but have been associated with unpleasant side effects and poor results in most patients. Recent advances in understanding the molecular biology of kidney cancer have resulted in the development of drugs that target known molecular pathways (targeted therapy). This review critically examines reports of clinical trials that have directly compared the new targeted "designer" drugs with previous standard therapies for this condition, to see if these drugs could be considered an advance in care.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2012

Calcineurin inhibitor minimisation, ie, reduction or withdrawal, versus continuation of calcineurin inhibitor treatment for liver transplant patients

Almost every liver transplant recipient is treated with either the drug tacrolimus or the drug cyclosporine to prevent rejection of the transplanted liver. These drugs are part of a group of drugs called calcineurin inhibitors. Both tacrolimus and cyclosporine have serious and common adverse effects and, therefore, dose reduction or discontinuation of these drugs is frequently applied in clinical practice. The aim of the review was to compare reduction or withdrawal of tacrolimus or cyclosporine without substitution with another immunosuppressive agent with continuation of tacrolimus or cyclosporine. Through systematic searches of medical databases we found one ongoing randomised clinical trial investigating total withdrawal of immunosuppressive drugs but, at the time of conducting this review, no trial results on the outcome measures of interest to this review were published. Thus, we cannot reach any conclusion on beneficial or harmful effects of calcineurin inhibitor minimisation for liver transplant recipient patients.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2012

Palbociclib (Ibrance) for advanced breast cancer: Overview

Palbociclib (trade name: Ibrance) has been approved in Germany since November 2016 for the treatment of advanced hormone receptor-positive breast cancer in women who cannot have chemotherapy, radiotherapy or further surgery.

Informed Health Online [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: March 23, 2017

Breast Cancer Treatment (PDQ®): Patient Version

Expert-reviewed information summary about the treatment of ductal carcinoma in situ and invasive breast cancer.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: March 24, 2017

Endometrial Cancer Treatment (PDQ®): Patient Version

Expert-reviewed information summary about the treatment of endometrial cancer.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: April 6, 2017

Childhood Astrocytomas Treatment (PDQ®): Patient Version

Expert-reviewed information summary about the treatment of childhood astrocytomas.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: April 7, 2017

Renal Cell Cancer Treatment (PDQ®): Patient Version

Expert-reviewed information summary about the treatment of renal cell cancer.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: December 23, 2016

Unusual Cancers of Childhood Treatment (PDQ®): Patient Version

Expert-reviewed information summary about the treatment of unusual cancers of childhood such as cancers of the head and neck, chest, abdomen, reproductive system, skin, and others.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: April 6, 2017

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...